As Teekay Tankers LTD Cl Af (TNK) Valuation Declined, Shareholder Berson & Corrado Investment Advisors Has Increased Position; As Edwards Lifesciences (EW) Share Value Rose, Shareholder British Columbia Investment Management Decreased Stake by $587,946

December 21, 2017 - By Michael Collier

British Columbia Investment Management Corp decreased its stake in Edwards Lifesciences Corp (EW) by 3.04% based on its latest 2017Q3 regulatory filing with the SEC. British Columbia Investment Management Corp sold 5,394 shares as the company’s stock rose 25.80% with the market. The institutional investor held 171,794 shares of the industrial specialties company at the end of 2017Q3, valued at $18.78 million, down from 177,188 at the end of the previous reported quarter. British Columbia Investment Management Corp who had been investing in Edwards Lifesciences Corp for a number of months, seems to be less bullish one the $23.96B market cap company. The stock decreased 0.83% or $0.95 during the last trading session, reaching $113.2. About 908,024 shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 15.41% since December 21, 2016 and is uptrending. It has underperformed by 1.29% the S&P500.

Berson & Corrado Investment Advisors Llc increased its stake in Teekay Tankers Ltd Cl Af (TNK) by 84.49% based on its latest 2017Q3 regulatory filing with the SEC. Berson & Corrado Investment Advisors Llc bought 360,875 shares as the company’s stock declined 21.54% while stock markets rallied. The institutional investor held 787,988 shares of the marine transportation company at the end of 2017Q3, valued at $1.28 million, up from 427,113 at the end of the previous reported quarter. Berson & Corrado Investment Advisors Llc who had been investing in Teekay Tankers Ltd Cl Af for a number of months, seems to be bullish on the $360.86 million market cap company. The stock decreased 1.10% or $0.015 during the last trading session, reaching $1.345. About 2.49M shares traded or 58.79% up from the average. Teekay Tankers Ltd. (NYSE:TNK) has declined 45.94% since December 21, 2016 and is downtrending. It has underperformed by 62.64% the S&P500.

Analysts await Edwards Lifesciences Corporation (NYSE:EW) to report earnings on February, 7. They expect $0.90 EPS, up 20.00% or $0.15 from last year’s $0.75 per share. EW’s profit will be $190.45 million for 31.44 P/E if the $0.90 EPS becomes a reality. After $0.84 actual EPS reported by Edwards Lifesciences Corporation for the previous quarter, Wall Street now forecasts 7.14% EPS growth.

British Columbia Investment Management Corp, which manages about $12.94 billion US Long portfolio, upped its stake in Agco Corp (NYSE:AGCO) by 15,130 shares to 57,286 shares, valued at $4.23 million in 2017Q3, according to the filing. It also increased its holding in Nucor Corp (NYSE:NUE) by 6,996 shares in the quarter, for a total of 274,439 shares, and has risen its stake in General Electric Co (NYSE:GE).

Among 27 analysts covering Edwards Lifesciences Corp (NYSE:EW), 20 have Buy rating, 1 Sell and 6 Hold. Therefore 74% are positive. Edwards Lifesciences Corp had 90 analyst reports since July 30, 2015 according to SRatingsIntel. The rating was downgraded by Zacks to “Hold” on Tuesday, September 22. The company was maintained on Wednesday, October 26 by Stifel Nicolaus. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Equal-Weight” rating given on Thursday, April 7 by Barclays Capital. The rating was maintained by RBC Capital Markets with “Buy” on Monday, July 10. The company was maintained on Thursday, July 27 by Canaccord Genuity. The firm has “Overweight” rating by Morgan Stanley given on Thursday, October 26. Canaccord Genuity maintained Edwards Lifesciences Corporation (NYSE:EW) rating on Monday, May 23. Canaccord Genuity has “Buy” rating and $132 target. As per Tuesday, June 27, the company rating was maintained by Canaccord Genuity. The stock has “Buy” rating by Nomura on Thursday, March 17. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, April 26 report.

Berson & Corrado Investment Advisors Llc, which manages about $396.59 million and $177.71M US Long portfolio, decreased its stake in Sector Spdr Health Fund (XLV) by 4,112 shares to 6,962 shares, valued at $569,000 in 2017Q3, according to the filing. It also reduced its holding in Enzo Biochem Inc (NYSE:ENZ) by 87,375 shares in the quarter, leaving it with 238,726 shares, and cut its stake in Tronox Ltd Class A.